277 related articles for article (PubMed ID: 27066977)
21. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of the atypical activation mechanism of KRAS
Bera AK; Lu J; Wales TE; Gondi S; Gurbani D; Nelson A; Engen JR; Westover KD
J Biol Chem; 2019 Sep; 294(38):13964-13972. PubMed ID: 31341022
[TBL] [Abstract][Full Text] [Related]
24. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
25. Interaction of a novel fluorescent GTP analogue with the small G-protein K-Ras.
Iwata S; Masuhara K; Umeki N; Sako Y; Maruta S
J Biochem; 2016 Jan; 159(1):41-8. PubMed ID: 26184075
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of the guanine nucleotide exchange reaction of Ras GTPase--evidence for a GTP/GDP displacement model.
Zhang B; Zhang Y; Shacter E; Zheng Y
Biochemistry; 2005 Feb; 44(7):2566-76. PubMed ID: 15709769
[TBL] [Abstract][Full Text] [Related]
27. High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site.
Chavan TS; Jang H; Khavrutskii L; Abraham SJ; Banerjee A; Freed BC; Johannessen L; Tarasov SG; Gaponenko V; Nussinov R; Tarasova NI
Biophys J; 2015 Dec; 109(12):2602-2613. PubMed ID: 26682817
[TBL] [Abstract][Full Text] [Related]
28. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
29. Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor.
Chen SY; Huff SY; Lai CC; Der CJ; Powers S
Oncogene; 1994 Sep; 9(9):2691-8. PubMed ID: 8058333
[TBL] [Abstract][Full Text] [Related]
30. Alternate mechanisms of ras activation are complementary and favor and formation of ras-GTP.
Patel G; MacDonald MJ; Khosravi-Far R; Hisaka MM; Der CJ
Oncogene; 1992 Feb; 7(2):283-8. PubMed ID: 1549350
[TBL] [Abstract][Full Text] [Related]
31. Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1.
Howes JE; Akan DT; Burns MC; Rossanese OW; Waterson AG; Fesik SW
Mol Cancer Ther; 2018 May; 17(5):1051-1060. PubMed ID: 29440291
[TBL] [Abstract][Full Text] [Related]
32. Activation of RalA is critical for Ras-induced tumorigenesis of human cells.
Lim KH; Baines AT; Fiordalisi JJ; Shipitsin M; Feig LA; Cox AD; Der CJ; Counter CM
Cancer Cell; 2005 Jun; 7(6):533-45. PubMed ID: 15950903
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.
Miller KA; Yeager N; Baker K; Liao XH; Refetoff S; Di Cristofano A
Cancer Res; 2009 Apr; 69(8):3689-94. PubMed ID: 19351816
[TBL] [Abstract][Full Text] [Related]
34. RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells.
Bjørndal B; Myklebust LM; Rosendal KR; Myromslien FD; Lorens JB; Nolan G; Bruland O; Lillehaug JR
Int J Cancer; 2007 Mar; 120(5):961-9. PubMed ID: 17149700
[TBL] [Abstract][Full Text] [Related]
35. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
36. Anti-Influenza Activity of the Ribonuclease Binase: Cellular Targets Detected by Quantitative Proteomics.
Ulyanova V; Shah Mahmud R; Laikov A; Dudkina E; Markelova M; Mostafa A; Pleschka S; Ilinskaya O
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167434
[TBL] [Abstract][Full Text] [Related]
37. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Li C; Vides A; Kim D; Xue JY; Zhao Y; Lito P
Science; 2021 Oct; 374(6564):197-201. PubMed ID: 34618566
[TBL] [Abstract][Full Text] [Related]
38. The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells.
Barlat I; Schweighoffer F; Chevallier-Multon MC; Duchesne M; Fath I; Landais D; Jacquet M; Tocque B
Oncogene; 1993 Jan; 8(1):215-8. PubMed ID: 7999142
[TBL] [Abstract][Full Text] [Related]
39. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.
Hocker HJ; Cho KJ; Chen CY; Rambahal N; Sagineedu SR; Shaari K; Stanslas J; Hancock JF; Gorfe AA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10201-6. PubMed ID: 23737504
[TBL] [Abstract][Full Text] [Related]
40. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
